pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antisense Oligonucleotide (ASO) · news · pharmadog
← back to Antisense Oligonucleotide (ASO)
News · Antisense Oligonucleotide (ASO)
83
stories
23h
nChroma halves headcount, calls time on trial of potential HBV ‘cure’
fiercebiotech
1d
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
1d
Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
fiercebiotech
4d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
7d
Deep dive: Cardiovascular calamities and catalysts
biospace
10d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
14d
AHA: Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
fiercebiotech
22d
Biogen set up for growth even without M&A but CEO won’t rule it out
biospace
22d
GSK vaccine sales miss expectations amid falling demand from adults
biospace
22d
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
biospace
23d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
27d
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
biospace
27d
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
28d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
28d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
28d
Why researchers may have found the biological culprit behind Angelman syndrome
fiercebiotech
29d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
29d
GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
biospace
Oct 20, 26
FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
fda press
Oct 19, 26
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
Oct 15, 26
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
biospace
Oct 8, 26
On the move: 4 rare disease companies hiring now
biospace
Sep 28, 26
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
biospace
Sep 23, 26
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
Sep 23, 26
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
Sep 23, 26
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
Sep 23, 26
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
Sep 18, 26
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
biospace
Sep 16, 26
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
Sep 16, 26
5 biotechs braving the commercial waters with product launches
biospace
← prev
page 1 of 3
next →